Known safety concerns, contraindications, and risk factors.
ARA-290 (cibinetide) is an investigational compound that completed Phase II but not Phase III clinical trials. Araim Pharmaceuticals has ceased operations. No pharmaceutical-grade source currently exists. All safety data below is derived from short-term clinical trials (up to 28 days) and preclinical research.
Active or Suspected Malignancy
ARA-290 activates anti-apoptotic survival pathways that could theoretically promote tumour cell survival. Use is strongly advised against in anyone with active or suspected cancer.
Pregnancy and Breastfeeding
No human reproductive or developmental toxicology data exists. Effects on foetal development are unknown. Use during pregnancy or breastfeeding is not recommended under any circumstances.
Severe Renal Impairment
The pharmacokinetics of ARA-290 in patients with severely reduced renal clearance have not been characterised, despite the peptide showing renoprotective signals in animal models.
Severe Cardiovascular Disease
While designed to avoid EPO's thrombotic risks, medical supervision is considered mandatory for individuals with severe cardiac conditions due to the experimental nature of the drug.
Competitive Athletes
ARA-290 is an EPO-derived peptide classified under WADA S0 (non-approved substances). Any use carries significant anti-doping consequences.